It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neutrophils are implicated in multiple homeostatic and pathological processes, but whether functional diversity requires discrete neutrophil subsets is not known. Here, we apply single-cell RNA sequencing to neutrophils from normal and inflamed mouse tissues. Whereas conventional clustering yields multiple alternative organizational structures, diffusion mapping plus RNA velocity discloses a single developmental spectrum, ordered chronologically. Termed here neutrotime, this spectrum extends from immature pre-neutrophils, largely in bone marrow, to mature neutrophils predominantly in blood and spleen. The sharpest increments in neutrotime occur during the transitions from pre-neutrophils to immature neutrophils and from mature marrow neutrophils to those in blood. Human neutrophils exhibit a similar transcriptomic pattern. Neutrophils migrating into inflamed mouse lung, peritoneum and joint maintain the core mature neutrotime signature together with new transcriptional activity that varies with site and stimulus. Together, these data identify a single developmental spectrum as the dominant organizational theme of neutrophil heterogeneity.
Differentiating neutrophil functional states is difficult. Here the authors show, using single cell RNA-sequencing and trajectory analyses, that mouse neutrophils can be presented as a transcriptome continuum rather than discrete subsets, but are affected by inflammation to express distinct transcriptional states.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Heidelberg University Hospital, Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
2 Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Harvard Medical School, Division of Immunology, Department of Microbiology and Immunobiology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
4 Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); VA Boston Healthcare System, Rheumatology Section, Boston, USA (GRID:grid.410370.1) (ISNI:0000 0004 4657 1992)
5 Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Division of Immunology, Boston Children’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
6 University of California San Francisco, Department of Microbiology & Immunology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
7 The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7)
8 Department of Cancer Immunology, Genentech, South San Francisco, USA (GRID:grid.418158.1) (ISNI:0000 0004 0534 4718)
9 Harvard Medical School, Department of Immunology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
10 Icahn School of Medicine at Mount Sinai, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
11 Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
12 Icahn School of Medicine at Mount Sinai, Immunology Institute and Tisch Cancer Institute, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
13 Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002)
14 University of California San Diego, Division of Biological Sciences, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
15 University of Massachusetts Medical School, Department of Pathology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
16 La Jolla Institute for Immunology, La Jolla, USA (GRID:grid.185006.a) (ISNI:0000 0004 0461 3162)
17 Ben-Gurion University of the Negev, Department of Life Sciences, Be’er Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511)
18 University of British Columbia, Department of Statistics, Vancouver, Canada (GRID:grid.17091.3e) (ISNI:0000 0001 2288 9830)
19 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, USA (GRID:grid.66859.34)
20 RIKEN Center for Integrative Medical Sciences, YCI Laboratory for Immunological Transcriptomics, Kanagawa, Japan (GRID:grid.509459.4) (ISNI:0000 0004 0472 0267)